Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by balainon Mar 14, 2018 12:39am
158 Views
Post# 27711115

RE:RE:RE:Stam/Chinese last quarter they reported it but

RE:RE:RE:Stam/Chinese last quarter they reported it but Hi agree Ret.

i am not too sure why we haven’t looked for a closer to date, maybe the board thinks we have what it takes (PL), maybe they know something we don’t as shareholders (like deal pending on Alstrm results)?

the one thing that I know is that if those rumoured outstanding Alstrm results don’t lead to an immediate deal, as I assume those over pregnant/ advanced discussions are pending on, i’ll be scratching my head. I will then assume that the double blind placebo data on IPF will result in the deal of the century... but at some point, and that’s probably the point for me, something needs to happen.

and if they are truly waiting to release Alstrm data to offset the failed SRAM deal, that will just be another disappointment for me.

i truly hope, over an over again, that the company will surprise us (with something positive). We always seem to get the worst case scenario out of a good news. I trust management focus on working relentlessly to deliver, but at some point they need to realize that they need help with a track record. Hopefully the board realizes that, and that PL can put his pride aside to get someone to close the long awaited deal.

cheers

balain
Bullboard Posts